Bioaffinity Technologies Stock Analysis
| BIAF Stock | USD 0.75 0.11 12.79% |
At this time, BioAffinity Technologies' Total Debt To Capitalization is most likely to increase significantly in the upcoming years. The BioAffinity Technologies' current Debt Equity Ratio is estimated to increase to 0.55, while Net Debt is projected to decrease to roughly 338.5 K. BioAffinity Technologies' financial risk is the risk to BioAffinity Technologies stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.27 | Current Value 0.25 | Quarterly Volatility 15.86771411 |
bioAffinity Technologies is undervalued with Real Value of 2.05 and Target Price of 6.0. The main objective of BioAffinity Technologies stock analysis is to determine its intrinsic value, which is an estimate of what bioAffinity Technologies is worth, separate from its market price. There are two main types of BioAffinity Technologies' stock analysis: fundamental analysis and technical analysis.
The BioAffinity Technologies stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and BioAffinity Technologies' ongoing operational relationships across important fundamental and technical indicators.
BioAffinity | Build AI portfolio with BioAffinity Stock |
BioAffinity Stock Analysis Notes
The company has price-to-book (P/B) ratio of 0.43. Some equities with similar Price to Book (P/B) outperform the market in the long run. bioAffinity Technologies recorded a loss per share of 13.83. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 19th of September 2025. bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company was founded in 2014 and is based in San Antonio, Texas. Bioaffinity Technologies operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 14 people. For more info on bioAffinity Technologies please contact the company at 210 698 5334 or go to https://www.bioaffinitytech.com.bioAffinity Technologies Investment Alerts
| BioAffinity Technologies generated a negative expected return over the last 90 days | |
| BioAffinity Technologies has high historical volatility and very poor performance | |
| BioAffinity Technologies has some characteristics of a very speculative penny stock | |
| BioAffinity Technologies has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies currently holds 1.5 M in liabilities. bioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 9.36 M. Net Loss for the year was (9.04 M) with profit before overhead, payroll, taxes, and interest of 1.89 M. | |
| bioAffinity Technologies currently holds about 214.4 K in cash with (7.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Latest headline from MacroaxisInsider: Acquisition by Anderson Robert A. of 11867 shares of BioAffinity Technologies at 1.58 subject to Rule 16b-3 |
BioAffinity Largest EPS Surprises
Earnings surprises can significantly impact BioAffinity Technologies' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-14 | 2024-06-30 | -0.17 | -0.19 | -0.02 | 11 | ||
2025-05-20 | 2025-03-31 | -0.17 | -0.1905 | -0.0205 | 12 | ||
2025-03-31 | 2024-12-31 | -0.14 | -0.19 | -0.05 | 35 |
BioAffinity Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Sprott Inc. | 2025-06-30 | 10 K | Tower Research Capital Llc | 2025-06-30 | 3.1 K | Citigroup Inc | 2025-06-30 | 1.5 K | Bank Of America Corp | 2025-06-30 | 205 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 100.0 | Ubs Group Ag | 2025-06-30 | 24.0 | Warberg Asset Management Llc | 2025-06-30 | 0.0 | Barclays Plc | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2025-03-31 | 0.0 | Geode Capital Management, Llc | 2025-06-30 | 125.5 K | Hanson Mcclain Inc | 2025-06-30 | 53.7 K |
BioAffinity Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.37 M.BioAffinity Profitablity
The company has Profit Margin (PM) of (2.17) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.59) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.59.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.88) | (1.97) | |
| Return On Capital Employed | (3.02) | (2.87) | |
| Return On Assets | (1.25) | (1.31) | |
| Return On Equity | (4.00) | (3.80) |
Management Efficiency
bioAffinity Technologies has return on total asset (ROA) of (0.7171) % which means that it has lost $0.7171 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.4518) %, meaning that it created substantial loss on money invested by shareholders. BioAffinity Technologies' management efficiency ratios could be used to measure how well BioAffinity Technologies manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.97. The BioAffinity Technologies' current Return On Capital Employed is estimated to increase to -2.87. At this time, BioAffinity Technologies' Other Assets are most likely to decrease significantly in the upcoming years. The BioAffinity Technologies' current Fixed Asset Turnover is estimated to increase to 5.46, while Non Currrent Assets Other are projected to decrease to roughly 15.1 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.79 | 6.08 | |
| Tangible Book Value Per Share | 0.94 | 0.99 | |
| Enterprise Value Over EBITDA | (1.24) | (1.30) | |
| Price Book Value Ratio | 3.82 | 4.01 | |
| Enterprise Value Multiple | (1.24) | (1.30) | |
| Price Fair Value | 3.82 | 4.01 | |
| Enterprise Value | 10.3 M | 9.1 M |
Evaluating the management effectiveness of BioAffinity Technologies allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The BioAffinity Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Technical Drivers
As of the 6th of February, BioAffinity Technologies shows the Risk Adjusted Performance of (0.19), coefficient of variation of (384.47), and Standard Deviation of 6.1. bioAffinity Technologies technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm bioAffinity Technologies treynor ratio, as well as the relationship between the value at risk and skewness to decide if bioAffinity Technologies is priced correctly, providing market reflects its regular price of 0.75 per share. As bioAffinity Technologies is a penny stock we also strongly suggest to validate its jensen alpha numbers.bioAffinity Technologies Price Movement Analysis
The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Moving Average is predictive technique used to analyze bioAffinity Technologies price data points by creating a series of averages of different subsets of BioAffinity Technologies entire price series.
bioAffinity Technologies Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioAffinity Technologies insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioAffinity Technologies' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases BioAffinity Technologies insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
BioAffinity Technologies Outstanding Bonds
BioAffinity Technologies issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. bioAffinity Technologies uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioAffinity bonds can be classified according to their maturity, which is the date when bioAffinity Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
BioAffinity Technologies Predictive Daily Indicators
BioAffinity Technologies intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioAffinity Technologies stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 37370.3 | |||
| Daily Balance Of Power | (1.00) | |||
| Rate Of Daily Change | 0.87 | |||
| Day Median Price | 0.75 | |||
| Day Typical Price | 0.75 | |||
| Price Action Indicator | (0.05) | |||
| Period Momentum Indicator | (0.11) |
BioAffinity Technologies Forecast Models
BioAffinity Technologies' time-series forecasting models are one of many BioAffinity Technologies' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioAffinity Technologies' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.BioAffinity Technologies Bond Ratings
bioAffinity Technologies financial ratings play a critical role in determining how much BioAffinity Technologies have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for BioAffinity Technologies' borrowing costs.| Piotroski F Score | 5 | Healthy | View |
| Beneish M Score | (4.11) | Unlikely Manipulator | View |
bioAffinity Technologies Debt to Cash Allocation
Many companies such as BioAffinity Technologies, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
bioAffinity Technologies currently holds 1.5 M in liabilities. bioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity.BioAffinity Technologies Total Assets Over Time
BioAffinity Technologies Assets Financed by Debt
The debt-to-assets ratio shows the degree to which BioAffinity Technologies uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.BioAffinity Technologies Debt Ratio | 25.0 |
BioAffinity Technologies Corporate Bonds Issued
Most BioAffinity bonds can be classified according to their maturity, which is the date when bioAffinity Technologies has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
BioAffinity Short Long Term Debt Total
Short Long Term Debt Total |
|
About BioAffinity Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how BioAffinity Technologies prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioAffinity shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioAffinity Technologies. By using and applying BioAffinity Stock analysis, traders can create a robust methodology for identifying BioAffinity entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.87) | (0.91) | |
| Operating Profit Margin | (0.86) | (0.90) | |
| Net Loss | (0.87) | (0.91) | |
| Gross Profit Margin | 0.42 | 0.58 |
Current BioAffinity Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BioAffinity analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BioAffinity analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Consensus | # of Analysts | |
| 6.0 | Hold | 1 | Odds |
Most BioAffinity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand BioAffinity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of bioAffinity Technologies, talking to its executives and customers, or listening to BioAffinity conference calls.
BioAffinity Stock Analysis Indicators
bioAffinity Technologies stock analysis indicators help investors evaluate how BioAffinity Technologies stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BioAffinity Technologies shares will generate the highest return on investment. By understating and applying BioAffinity Technologies stock analysis, traders can identify BioAffinity Technologies position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 2.8 M | |
| Long Term Debt | 20.2 K | |
| Common Stock Shares Outstanding | 404.3 K | |
| Total Stockholder Equity | 2.6 M | |
| Total Cashflows From Investing Activities | -79.1 K | |
| Tax Provision | 11.7 K | |
| Property Plant And Equipment Net | 1.6 M | |
| Cash And Short Term Investments | 1.1 M | |
| Cash | 1.1 M | |
| Accounts Payable | 987.3 K | |
| Net Debt | 395.9 K | |
| 50 Day M A | 1.3443 | |
| Total Current Liabilities | 3.1 M | |
| Other Operating Expenses | 18.3 M | |
| Non Current Assets Total | 3.8 M | |
| Non Currrent Assets Other | 19.7 K | |
| Stock Based Compensation | 989.7 K |
Complementary Tools for BioAffinity Stock analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |